Arialys Therapeutics key facts
as of Oct 2026- Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsychiatric diseases.
- Arialys Therapeutics is valued at approximately $112.0M as of Oct 2026, set at its seed round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $72.0M across 2 recorded rounds; the latest was Early Stage VC ($14.8M) in Jun 2025.
- Notable investors include Alexandria Venture Investments, Johnson & Johnson JJDC, MPM BioImpact, Alexandria Real Estate Equities, Avalon Bioventures — 6 tracked in total.
- Arialys Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Jul 2025 ($14.8M sold to 7 investors).
- Status: Privately Held (backing).
Valued at $112.0M at its seed round, Jun 2025. Nothing has traded since.
- ·Watch Arialys Therapeutics: the Monday email on marks, rounds and moves
Arialys Therapeutics funding rounds
2 roundsArialys Therapeutics valuation
Arialys Therapeutics was valued at $112 million at its seed round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Arialys Therapeutics raised?
Arialys Therapeutics has raised $72 million in total; 2 of its rounds are on record. The largest on record was a $14.8 million early-stage round in Jun 2025.
Arialys Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in Jul 2025 ($14.8 million sold to 7 investors).
Arialys Therapeutics investors
6 investors are on record for Arialys Therapeutics, including Alexandria Venture Investments, Johnson & Johnson JJDC, MPM BioImpact and Alexandria Real Estate Equities. The early-stage round in Jun 2025 drew 7 investors.
About Arialys Therapeutics
Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsychiatric diseases. The company specializes in the field of neuroscience and characterizes the nature and prevalence of pathogenic auto-antibody activity in the central nervous system converged network services, enabling clients to avail advanced breakthrough therapies for a variety of central nervous system disorders and treating neuropsychiatric disorders driven by autoimmune diseases.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- arialysrx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.